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Major Histocompatibil ity Complex I and II Expression and
Lymphocytic Subtypes in Muscle of Horses with Immune-Mediated
Myositis
S.A. Durward-Akhurst, C.J. Finno, N. Barnes, J. Shivers, L.T. Guo, G.D. Shelton, and S.J. Valberg
Background: Major histocompatibility complex (MHC) I and II expression is not normally detected on sarcolemma, but
is detected with lymphocytic infiltrates in immune-mediated myositis (IMM) of humans and dogs and in dysferlin-deficient
muscular dystrophy.
Hypothesis/Objectives: To determine if sarcolemmal MHC is expressed in active IMM in horses, if MHC expression is
associated with lymphocytic subtype, and if dysferlin is expressed in IMM.
Animals: Twenty-one IMM horses of Quarter Horse-related breeds, 3 healthy and 6 disease controls (3 pasture myopathy,
3 amylase-resistant polysaccharide storage myopathy [PSSM]).
Methods: Immunohistochemical staining for MHC I, II, and CD4+, CD8+, CD20+ lymphocytes was performed on
archived muscle of IMM and control horses. Scores were given for MHC I, II, and lymphocytic subtypes. Immunofluorescent
staining for dysferlin, dystrophin, and a-sarcoglycan was performed.
Results: Sarcolemmal MHC I and II expression was detected in 17/21 and 15/21 of IMM horses, respectively, and in
specific fibers of PSSM horses, but not healthy or pasture myopathy controls. The CD4+, CD8+, and CD20+ cells were pre-
sent in 20/21 IMM muscles with CD4+ predominance in 10/21 and CD8+ predominance in 6/21 of IMM horses. Dysferlin,
dystrophin, and a-sarcoglycan staining were similar in IMM and control muscles.
Conclusions and clinical importance: Deficiencies of dysferlin, dystrophin, and a-sarcoglycan are not associated with IMM.
Sarcolemmal MHC I and II expression in a proportion of myofibers of IMM horses in conjunction with lymphocytic infiltra-
tion supports an immune-mediated etiology for IMM. The MHC expression also occured in specific myofibers in PSSM
horses in the absence of lymphocytic infiltrates.
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Suspected immune-mediated myositis (IMM) wasfirst described in horses in 2007.1 Affected horses
were predominantly Quarter Horses or related breeds
and presented with severe atrophy of gluteal and epax-
ial muscles and high serum creatine kinase (CK) and
aspartate transaminase (AST) activities. An immune-
mediated basis for muscle degeneration was suspected
because myofibers within muscle biopsy specimens of
IMM horses contained lymphocytic infiltrates, with on
average more CD4+ than CD8+ lymphocytes.1 Lym-
phocytic infiltrates typically are found in the muscle of
humans and dogs affected with various types of inflam-
matory and immune-mediated myositis with specific
lymphocytic subtypes predominating in some forms and
not others. For example, a predominant CD4+ infiltrate
is described in masticatory muscle myositis of dogs
(CMMM) and dermatomyositis (DM), whereas a pre-
dominant CD8+ infiltrate is found in polymyositis (PM)
in dogs.2
Lymphocytic infiltrates, however, are not restricted to
immune-mediated myositis and are also a feature of
inflammatory myopathies caused by infectious agents
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such as Toxoplasma gondii and Neospora caninum.3
Inflammatory myopathies secondary to infectious causes,
however, often have eosinophilic infiltrates in addition to
lymphocytes.3 Eosinophils also have been found in
inflammatory myopathies such as CMMM in dogs3 and
eosinophilic polymyositis in humans.4 Muscle inflamma-
tion also may be a predominant pathological finding in
dysferlin-deficient muscular dystrophy in humans.5,6
Expression of major histocompatibility complex class
I (MHC I) and in some cases MHC II on the sar-
colemma and occasionally within muscle fibers is
another diagnostic tool for assessing many forms of
immune-mediated myositis in humans and dogs.7,8
Mature muscle fibers in healthy individuals are quite
unique in that MHC antigens are not normally detect-
able on the sarcolemma, and staining is limited to the
capillary network and endothelial cells of blood ves-
sels.9,10 Major histocompatibility complex I, however, is
detectable on the sarcolemmal surface of developing
myoblasts,11 and regenerating myofibers.10 In addition
to sarcolemmal expression of MHC I and II in
immune-mediated myopathies, MHC class I expression
also occurs in some forms of muscular dystrophy such
as limb-girdle muscular dystrophy caused by a mutation
in the dysferlin gene.6,12
The purpose of our study was to further explore the
pathogenesis of IMM in horses by determining (1) if
MHC I or II expression or both is detectable on the
sarcolemma of myofibers of horses with active IMM,
(2) whether there is a relationship between MHC
expression and the predominant subtype of lymphocytes
within muscle infiltrates, and (3) whether dysferlin is
expressed on the myofibers of horses with IMM.
Materials and Methods
Horses
IMM. Records of muscle biopsy specimens submitted to the
University of Minnesota Neuromuscular Laboratory (NMDL)
between 1995 and 2013 were reviewed to identify the breed, age, sex,
and clinicopathologic abnormalities of horses with a primary diag-
nosis of IMM. All muscle samples had been shipped overnight on
frozen gel packs to the NMDL, where they were frozen in isopen-
tane precooled in liquid nitrogen and stored at 80°C until further
processing. The diagnosis of IMM was based on identification of
lymphocytic infiltration having an endomysial or perimysial distri-
bution with invasion of nonnecrotic fibers or surrounding blood ves-
sels in hematoxylin and eosin (HE)-stained muscle sections.
Twenty-one muscle biopsy specimens from 18 Quarter Horses
and 3 Paint horses that had a history of muscle atrophy were
selected for inclusion in the study based on the large number of
lymphocytes invading myofibers, well-preserved frozen muscle tis-
sue with minimal freeze artifact, and the absence of evidence of
polysaccharide storage myopathy (PSSM) in periodic acid Schiff’s
stains. The mean age was 5.0 years (range, 0.5–19 years). There
were 10 mares, 5 stallions, and 6 geldings. Muscle biopsies were
from the gluteal (n = 7), epaxial (n = 2), and semimembranosus
(n = 12) muscles. Median reported serum CK activity was
3,165 U/L (range, 123–130,000 U/L) and median serum AST
activity was 3,356 U/L (range, 460–79,700 U/L). Eighty-nine per-
cent (18/21) of horses with reported CK or AST results had
increased enzyme activities.
Healthy and Disease Controls
Samples from the gluteus medius muscle of 3 Quarter Horses, 2
mares, and 1 gelding, with a mean age of 4.7 years (range, 4–
6 years) were selected as healthy controls. The disease controls
consisted of 3 horses with acute seasonal pasture myopathy and 3
horses with amylase-resistant polysaccharide storage myopathy
(PSSM). The 3 horses with pasture myopathy consisted of 1 Quar-
ter Horse, 1 Paint horse, and 1 Appaloosa (2 geldings and 1 stal-
lion) with a mean age of 5.5 years (range, 1–13 years). Samples
were from the gluteus medius (n = 2) and semimembranosus
(n = 1) muscles. The 3 geldings with PSSM consisted of 1 Quarter
Horse and 2 Appaloosas with a mean age of 5 years (range, 3–
7 years). All samples were from the semimembranosus muscle.
Review of archived stains determined that muscle samples from
horses with pasture myopathy had excessive myofiber lipid in oil
Red O stains and evidence of acute myodegeneration without
regeneration in HE-stained samples. The PSSM muscle samples
did not contain regenerating myofibers, based on the absence of
small basophilic myofibers with prominent central nuclei in HE-
stained sections.
Muscle Analysis
Immunohistochemistry. Immunohistochemical (IHC) staining
was performed on 10-lm thick frozen sections that were fixed in
acetone (75%) and ethanol (25%) at 4°C for 10 min and had non-
specific binding blocked with normal goat serum (1 : 10). Muscle
sections were incubated with monoclonal antibodies for MHC
class I (mouse anti-horse CVS22), MHC class II (mouse anti-horse
CVS20), CD4+ (mouse anti-horse HB61A), CD8+ (mouse anti-
horse CVS8), and CD20+ (rabbit anti-horse). Secondary antibodies
against MHC I, MHC II, CD4+, CD8+ (horseradish peroxidase
goat anti-mouse IgG), and CD20+ (HRP goat anti-rabbit IgG)
were from EnVision.a Immunoreactivity was detected with 3-
amino-9-ethylcarbazole. Slides were counterstained with Mayer’s
hematoxylin. Positive control tissue consisted of normal adult
horse tonsil. Negative controls used dilute negative control mouse
(or rabbit for CD20+) fraction in place of the primary antibody.
Because staining for the macrophage marker MAC387 cross reacts
with other inflammatory cells, histochemical staining for macro-
phages was performed with the acid phosphatase reaction.13
Immunofluorescent staining. Immunofluorescent staining for sar-
colemmal localization of dysferlin, alpha sarcoglycan, and dys-
trophin was performed on cryopreserved muscle samples from 5
Quarter Horses with IMM and 1 control horse using acetone/
methanol fixation. Antibodies included NCL-Hamlet and NCL
Hamlet 2 monoclonal anti-dysferlin antibodies,b a polyclonal anti-
body against alpha sarcoglycan,c,14 and a monoclonal antibody
against the rod domain of dystrophin (DYS1d) using methods pre-
viously described.15 Slides were assessed for the presence or
absence of dysferlin, dystrophin, and alpha sarcoglycan on the sar-
colemma compared to control muscle.
Assessment of MHC I and II
A scoring system was devised to assess both the percentage of
fibers that had some degree of sarcolemmal staining for MHC as
well as to assess the extent of MHC staining around the periphery
of a myofiber. The whole muscle section was examined at 209
magnification and 3 separate areas with the most extensive MHC
staining and least cellular infiltrate were selected. These selection
criteria were used to avoid confusion of MHC staining of lympho-
cytes with MHC staining of the sarcolemma. Each selected area
was then examined at 409 magnification to estimate the number
of myofibers with MHC staining on some or all of the sarcolemma
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and scored using: score 0 (none positive), score 1 (<25% myofibers
positive), score 2 (25–50% positive), score 3 (51–75% positive),
and score 4 (>75% positive). In addition, the average extent to
which sarcolemmal staining for MHC extended around the sar-
colemma was estimated for all fibers in the region and scored
according to 0 (no positive sarcolemma staining), score 1 (<25%
of sarcolemma staining positive), score 2 (25–50% of sarcolemma
staining positive), score 3 (51–75% staining positive), and score 4
(>75% staining positive). The myofiber and sarcolemma scores for
each objective field were multiplied, and then summed to produce
an overall MHC I and MHC II score (maximum score of 48).
Assessment of Inflammatory Cells
Vascular Cuffing. Three areas with the most extensive cellular
infiltration surrounding vessels were selected at 209 magnification.
Each selected area was then examined at 409 magnification and
the percentage of the specific lymphocyte subtype (or macro-
phages) that stained positively of the total number of mononuclear
cell infiltrates in the area was estimated.
Myofiber Infiltrates. To compare the predominance of lympho-
cyte subtypes and macrophages with respect to the total mononu-
clear infiltrates, the whole muscle section was examined at 209
magnification and the 3 areas with the most extensive myofiber
cellular infiltration were selected. Each selected area then was
examined at 409 magnification and the percentage of the specific
lymphocyte subtype (or macrophages) that stained positively of
the total number of mononuclear cell infiltrates in the area was
estimated according to: score 0 (none positive), score 1 (<25% of
cells positive), score 2 (25–50% positive), score 3 (51–75% posi-
tive), and score 4 (>75% positive). To also assess the amount of
inflammation in the areas examined, a score also was given for the
total number of inflammatory cells in the field; score 0 (no inflam-
matory cells), score 1 (<25% of the field), score 2 (25–50% of the
field), score 3 (51–75% of the field), and score 4 (>75% of the
field). For each field, the scores for the percentage of cells staining
positively and the percentage of the field containing inflammatory
cells were multiplied, and the scores for the fields in each horse
then were summed to produce an overall myofiber infiltrate score
(maximum total score of 48).
Archived PAS stains were examined from horses with PSSM to
compare the distribution of the myofibers with PAS-positive inclu-
sions with the distribution of MHC I- and II-positive fibers.
Statistical Analysis
Based on Shapiro-Wilk testing, data were not normally dis-
tributed. A Mann-Whitney U-test was used to compare scores for
lymphocytic subtypes within muscle of IMM cases and scores for
MHC, lymphocytes, and macrophages between IMM cases and
disease controls. A Spearman Correlation was used to assess the
relationship between the cell type and MHC class. All statistical
analyses were performed using commercial software.e Significance
was set at P = .05.
Results
MHC Immunohistochemistry
Healthy Control Horses. Vascular endothelium stained
positively for MHC I and MHC II, whereas MHC I or II
staining was not observed on the sarcolemma of myofibers
of healthy control horses (Fig 1A).
IMM Horses. Vascular endothelium and mononu-
clear cells were darkly stained for MHC I and MHC II
in IMM horses (Fig 2A,B). There was a wide range of
MHC I and II staining of the sarcolemma within the
same muscle biopsy and among different horses with
IMM (Figs 1C–F, 3A,B). Both nondegenerate and
degenerate myofibers had MHC I or II sarcolemmal
staining in IMM horses. Fibers with MHC I or II sar-
colemmal staining were scattered throughout the biopsy
specimens in areas without mononuclear infiltrates
(Fig 1C–F) and concentrated in areas with infiltrates
(Fig 3A,B). Fibers with MHC I sarcolemmal staining
did not consistently have MHC II staining (Fig 1D,E).
In regions with minimal lymphocytic infiltrates, some
degree of MHC I sarcolemmal staining was present in
81% (17/21) of IMM horses and MHC II staining was
present in 71% (15/21) of IMM horses. The MHC I
scores were higher than MHC II scores in 82% (14/17)
of IMM horses that had myofibers staining for MHC
(Table 1).
Disease Control Horses. The MHC I staining was not
present in muscle samples from horses with seasonal
pasture myopathy (Fig 1B), but MHC II staining was
observed in a few degenerating myofibers of 2 horses
with seasonal pasture myopathy (Table 1). Sarcolemmal
and aggregates of cytoplasmic MHC I and II staining
were observed in the same myofibers of all 3 PSSM
horses (Fig 4B,C; Table 1). Unlike IMM cases, myofi-
bers with MHC staining were often clustered along the
edge of muscle fascicles. In regions containing fibers
with abnormal polysaccharide (Fig 4A), the cytoplasm
had stippled MHC staining and the fibers with MHC
staining did not appear to be regenerating based on the
review of HE sections.
Mononuclear Cell Histochemistry and
Immunohistochemistry
Healthy Control Horses. Macrophages and CD4+
and CD8+ lymphocytes were not observed near blood
vessels or among myofibers in healthy control horses. A
muscle sample from 1 control horse had a few CD20+
lymphocytes between myofibers.
IMM Horses. Vascular Cuffing. Mononuclear cells,
predominantly lymphocytes, were present around at
least 1 blood vessel in the muscle biopsy specimens of
all IMM horses. Only a few macrophages were present
around blood vessels in IMM horses (Fig 2F). The
CD4+ cells were present around blood vessels in 76%
(16/21) of IMM horses, CD8+ cells in 71% (15/21),
and CD20+ cells in 62% (13/21) of IMM horses
(Fig 2C,D,E).
Myofiber Infiltrates. Mononuclear cell infiltrates were
present around or in myofibers in 95% (20/21) of mus-
cle samples from IMM horses. One IMM case only had
vascular cuffing. Five horses had >50% of the biopsy
specimen consisting of inflammatory infiltrates com-
prised of CD4+, CD8+, CD20+, and macrophages
(Fig 3C,D,E,F). In 48% (10/21) of IMM horses, CD4+
lymphocytes predominated over CD8+ and CD20+ cells
and in 28% (6/21) of IMM horses CD8+ lymphocytes
predominated (assessed by comparison of scores within
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individuals). The median score for CD4+ lymphocytes
in IMM horses was not significantly different from
CD8+ scores (P = .35), CD20+ lymphocytes (P = .07),
or macrophages (P = .90) in IMM horses (Table 1).
Scores for CD8+ and CD20+ lymphocytes (P = .22),
CD8+ lymphocytes and macrophages (P = .36), and
CD20+ lymphocytes and macrophages (P = .07) in
IMM horses were similar (Table 1). The CD4+ lympho-
cyte score was positively correlated with CD8+ lympho-
cyte score (r = 0.53, P = .01; Fig 5) and macrophage
score (r = 0.46, P = .037). No significant correlation
between CD4+ and CD20+ scores was identified
(r = 0.38, P = .09). The CD8+ lymphocyte score was
positively correlated with CD20+ lymphocyte score
(r = 0.70, P = <.001) and macrophage score (r = 0.64,
P = .002).
The MHC I scores were positively correlated with
MHC II scores (r = 0.89, P = <.001; Fig 5) and CD8+
(r = 0.64, P = .002) and CD20+ (r = 0.66, P = .001) lym-
phocyte and macrophage scores (r = 0.70, P = <.001).
The MHC I scores were not significantly correlated
with CD4+ (r = 0.22, P = .34) lymphocyte scores. The
MHC II scores were positively correlated with CD8+
(r = 0.59, P = .005), CD20+ (r = 0.61, P = .004) lympho-
cyte and macrophage (r = 0.70, P = <.001) scores. The
MHC II scores were not significantly correlated with
CD4+ (r = 0.11, P = .63) lymphocyte scores.
Disease Control Horses
In seasonal pasture myopathy horses, CD4+ lym-
phocytes were not observed in any horses. No CD8+
or CD20+ lymphocytes were observed in the muscles
of 2 horses, whereas 1 horse had a few CD8+ and
CD20+ lymphocytes in the muscle sample. A few
macrophages were identified in necrotic myofibers in
all horses.
In PSSM horses, a few CD4+ and CD8+ lymphocytes
were present in muscle samples of 1 of the 3 PSSM
horses. Two of 3 PSSM horses had a few CD20+ lym-
phocytes. All 3 PSSM horses had a few scattered
macrophages in myofibers.
A B
C D
E F
Fig 1. Control and immune-mediated myositis (IMM) horses: (A) Major histocompatibility complex (MHC) I staining of a healthy con-
trol muscle showing endothelial staining of capillaries but no staining of the sarcolemma. (B) MHC I staining of a pasture myopathy dis-
ease control muscle showing endothelial staining of capillaries but no staining of the sarcolemma of degenerate myofibers. (C) Focal
sarcolemmal MHC I staining of an individual myofiber in a horse with IMM (IMM horse 1). (D) Generalized MHC I staining of the sar-
colemma in a horse with IMM (IMM horse 2). (E) A lack of sarcolemma MHC II staining in a serial section of muscle from the IMM
horse 2. (F) MHC II staining of an individual degenerating myofiber containing mononuclear infiltrates (IMM horse 3).
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Dysferlin, Dystrophin, and alpha Sarcoglycan
Compared to control muscle, muscle samples from all
IMM horses tested showed a normal pattern of uniform
sarcolemmal staining for dysferlin, dystrophin, and
alpha sarcoglycan (Fig 6).
Discussion
Our results expand upon the previous study of
suspected IMM in horses1 and support an immune-
mediated basis for this disorder in Quarter Horses.
Similar to cases of immune-mediated myopathies in
humans16 and dogs,3 infiltrates of CD8+ and CD4+ T
cells are observed in myofibers of IMM horses and,
when inflammatory infiltrates are present, the majority
of Quarter Horses with IMM express detectable MHC I
or II on the sarcolemma of some myofibers. This is
important because MHC expression normally is not
detectable on mature skeletal muscle fibers,7,9,11 but is
detectable on myofibers of humans and dogs with
immune-mediated myopathies.8,17,18 Investigations into
immune-mediated myopathies in humans and dogs have
found antigen processing and presentation by myofibers
expressing MHC.19,20 Thus, MHC expression in myofi-
bers of horses with IMM suggests that these fibers have
become immunologically activated and could serve as
antigen-presenting cells, presenting autoantigens to
inflammatory cells.8,20
Overexpression of MHC I is not specific to inflamma-
tory myopathies, however, and may also occur in dys-
trophin-deficient muscular dystrophy,9 some human
limb-girdle muscular dystrophies,4 and in limb-girdle
muscular dystrophy caused by a dysferlin deficiency.6
The histopathology of dysferlinopathy bears a resem-
blance to IMM in horses in that infiltrates of CD4+
lymphocytes can be present together with MHC I and
rarely with MHC II expression on myofibers.6,12 A lack
of dysferlin on the sarcolemma, a characteristic of dys-
ferlinopathies, was not identified in immunofluorescent
stains of IMM horse muscle. Neither do our results
support dystrophin- or sarcoglycan-deficient muscular
A B
C D
E F
Fig 2. Immune-mediated myositis (IMM) horse 3. (A) Major histocompatibility complex (MHC) I staining of the endothelium and the
mononuclear infiltrates that surround two arterioles. (B) MHC II staining of the endothelium and the mononuclear infiltrates that sur-
round two arterioles. (C) Immunohistochemical (IHC) staining for many CD4+ lymphocytes that are surrounding the arterioles. (D) IHC
staining of a small number of CD8+ lymphocytes surrounding the arterioles. (E) IHC staining of a small number of CD20+ lymphocytes
found scattered around arterioles. (F) Acid phosphatase staining of macrophages (aggregates of deep red stain) around an arteriole.
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dystrophy as a cause of IMM because dystrophin and
alpha sarcoglycan were clearly evident on the sar-
colemma of IMM-affected horses.
The MHC II antigens typically are restricted to anti-
gen-presenting cells of the immune system and interact
with CD4+ lymphocytes. The MHC II staining of the
sarcolemma was apparent in nondegenerate myofibers
of some IMM horses as well as in the degenerate myofi-
bers of IMM and some disease control horses. In other
species, MHC II sarcolemmal staining does not appear
to be as consistent a feature of inflammatory myopa-
thies as MHC I sarcolemmal staining. When present,
however, MHC II is highly specific for idiopathic
inflammatory myopathies.21 Although scores for MHC
A B
C D
E F
Fig 3. Immune-mediated myositis (IMM) horse 2. (A) Major histocompatibility complex (MHC) I staining of mononuclear infiltrates that
is so dense it obscures potential sarcolemmal MHC I staining. (B) MHC II staining of mononuclear infiltrates without evident MHC II sar-
colemmal staining. (C) Immunohistochemical (IHC) staining of numerous CD4+ lymphocytes in the endomysium and within myofibers.
(D) IHC staining of CD8+ lymphocytes in the endomysium. (E) IHC staining of a few CD20+ lymphocytes scattered in the endomysium.
(F) Acid phosphatase staining of numerous macrophages (red aggregates) infiltrating myofibers.
Table 1. Major histocompatibility complex (MHC) I and II, lymphocyte and macrophage scores of myofiber infil-
trates in immune-mediated myositis (IMM) horses. The higher the MHC scores the more fibers with MHC sarcolem-
mal staining. The higher the lymphocyte or macrophage score, the higher the proportion of mononuclear cells of that
specific subtype (CD4+, CD8+, CD20+, or macrophages) was relative to the total number of inflammatory cells. There
was no significant difference between scores for MHC I versus II staining or among lymphocyte subpopulations in
IMMmuscle indicating most IMMmuscle had a mixture of inflammatory cell infiltrates.
IMM horses MHC I MHC II CD4+ CD8+ CD20+ Macrophages
Maximum score 48 48 48 48 48 48
Median  SD 9  12 7  10 14  9 8  9 7  7 13  13
Range 0–44 0–40 0–41 0–32 0–24 0–41
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A B C
Fig 4. Polysaccharide storage myopathy (PSSM) horse. (A) Abnormal Periodic acid Schiff (PAS) positive inclusions in myofibers.
(B) Major histocompatibility complex (MHC) I staining of the sarcolemma and granular material within myofibers. (C) MHC II staining
of the sarcolemma and granular material in the same fibers.
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Fig 5. Correlation between CD4+ and CD8+ lymphocyte and major histocompatibility complex (MHC) class I and II scores. MHC I
scores were positively correlated with MHC II scores (r = 0.89, P < .001). CD4+ scores were positively correlated with CD8+ scores
(r = 0.53, P = .01).
Fig 6. Immunofluorescent staining of immune-mediated myositis (IMM) (horse 2) and healthy control muscle for localization of dysferlin,
dystrophin, and alpha sarcoglycan. Cryosections stained with antibodies against dysferlin, dystrophin, and alpha sarcoglycan show compa-
rable staining of the sarcolemma in IMM and control horse muscle.
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II expression correlated with scores for MHC I expres-
sion, MHC I and II expression did not necessarily colo-
calize to the same myofibers in IMM horses.
The MHC expression on the sarcolemma of myofi-
bers of IMM horses was not uniform and often only
involved scattered myofibers or a portion of the sar-
colemma. Variability in MHC expression with immune-
mediated myopathies may relate to the degree of
cytokine expression in myofibers, type of fibers affected,
severity of inflammation or stage of disease.21 Cytokines
can up-regulate MHC I and may play a role in non-
specific MHC I expression.20 In dogs with acute, severe
CMMM, MHC I and II staining commonly occurs in
>70% of myofibers, whereas in dogs with more chronic
disease, MHC I and II staining is much less extensive.8
Unfortunately, the onset of clinical signs relative to the
time of muscle biopsy was not recorded for many of the
cases in our study, and it was not possible to determine
if there was a temporal relationship between time of
biopsy, the amount of MHC staining on the sar-
colemma, and time course of infiltration of myofibers
with lymphocytes. Because the presence of lymphocytic
infiltrates was an inclusion criterion for the study, it is
not possible to know whether MHC I or II expression
occurred without active inflammation, but subjectively
it appeared that those biopsy specimen with the most
inflammation usually had the highest MHC expression
and those with the least infiltrates usually had the least
MHC expression. In addition, sarcolemmal membrane
integrity is important for reliable MHC antibody bind-
ing, and variable MHC staining may have been related
to the degradation of some of the muscle samples
before being frozen or during shipping. To manage this
possibility, IMM samples selected for inclusion in the
present study were chosen such that they had minimal
shipping artifacts, but delay in freezing could have
impacted the results in some biopsy specimens.
Most horses with IMM have increased muscle
enzyme activities and it was important to rule out rhab-
domyolysis alone as a cause for upregulation of MHC
on myofibers. Horses with PSSM and pasture myopathy
have rhabdomyolysis without marked myofiber infiltra-
tion by lymphocytes. Neither MHC class I or II were
detected in normal-appearing muscle fibers of horses
with PSSM or pasture myopathy. Interestingly, clusters
of mature myofibers from horses with PSSM expressed
MHC class I and II in the absence of any lymphocytic
infiltrates and in the absence of regenerative features
such as prominent centrally displaced nuclei or basophi-
lic cytoplasm in HE-stained sections. The distribution
of MHC-positive myofibers in PSSM horses was very
similar to the distribution of fibers with aggregates of
abnormal polysaccharide. A number of protein aggre-
gates have been found in myofibers of horses with type
1 PSSM including myoglobin and desmin, suggesting
that the cytoplasmic aggregates of MHC protein could
be a nonspecific finding.22 Another possibility is that
sarcolemmal MHC expression in fibers with abnormal
polysaccharide results from inflammatory cytokines pro-
duced because of the presence of the abnormal polysac-
charide and leading to MHC upregulation. The lack of
cellular inflammatory response in the face of MHC I or
II expression, however, suggests that the sarcolemmal
MHC:peptide complexes are recognized as ‘self’ pep-
tides in PSSM horses and therefore no additional
immune response is targeted toward these myofibers. A
further explanation for a lack of inflammatory response
in the face of MHC expression could be a lack of
upregulation of those proinflammatory cytokines that
directly incite an immune response.20,23 Major histo-
compatibility complex expression has been found to
occur in other myopathies that do not have an immune-
mediated etiology, and the reason for this expression is
not fully understood.21
Scores for MHC I expression were significantly corre-
lated with scores for predominance of CD8+ lympho-
cytes, and considering that CD8+ lymphocytes require
MHC I expression for activation this observation is not
surprising. However, scores for MHC II expression
were not correlated with scores for predominance of
CD4+ lymphocytes in IMM muscle biopsy specimens
although CD4+ lymphocytes require MHC II expres-
sion for activation. This could be because of the fact
that both CD8+ and CD4+ lymphocytes were present in
significant numbers in IMM muscle compared with con-
trols, with 48% of IMM horses having a predominance
of CD4+ cells compared to CD8+ and CD20+ lympho-
cytes. The mixed population of CD4+ and CD8+ lym-
phocytes in horses with IMM suggests that multiple
immune-mediated events lead to myofiber destruction.
The CD8+ lymphocytes lead to direct cell-mediated
cytotoxicity and the CD4+ cells typically mediate dis-
ease by interaction with B cells and the secondary anti-
body response. In many of the immune-mediated
myopathies of humans and dogs, there is a characteris-
tic predominance of either CD4+ or CD8+ lympho-
cytes.24 For example, PM is characterized by a
predominantly CD8+ infiltrate25 and DM and CMMM
are characterized by predominantly CD4+ lymphocytic
infiltrates.3,26 Although CD4+ cells predominate in
CMMM, affected masticatory muscle are reported to
have higher MHC class I than II scores suggesting that
there may not be a strong correlation between MHC I
and II expression and scores for CD8+ and CD4+ lym-
phocytes in muscle biopsy specimens.8 Dermatomyositis
is relatively unique in that it typically presents
with characteristic skin lesions in addition to muscle
weakness.16
In conclusion, MHC I and II expression occur in
mature nondegenerate myofibers of horses with IMM
in conjunction with a phase of active lymphocytic infil-
tration, findings that together support an immune-
mediated etiology for the disease. Unlike IMM, MHC
expression in specific myofibers of PSSM horses occurs
in the absence of lymphocytic infiltrates. Because the
degree of MHC sarcolemmal expression varies in
IMM-affected horses and also is present in horses with
PSSM, MHC staining alone is not diagnostic for
IMM in horses. Muscular dystrophies associated with
dysferlin, dystrophin, and sarcoglycan deficiencies were
ruled out based on normal IF staining of IMM muscle
samples.
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